Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.

Breast cancer recurrence (BCR) is a common treatment outcome despite curative-intent primary treatment of non-metastatic breast cancer. Currently used prognostic and predictive factors utilize tumor-based markers, and are not optimal determinants of risk of BCR. Germline-based copy number aberration...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yadav Sapkota, Sunita Ghosh, Raymond Lai, Bradley P Coe, Carol E Cass, Yutaka Yasui, John R Mackey, Sambasivarao Damaraju
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/2285fe0cfbbf425995582c081c331530
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2285fe0cfbbf425995582c081c331530
record_format dspace
spelling oai:doaj.org-article:2285fe0cfbbf425995582c081c3315302021-11-18T08:01:15ZGermline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.1932-620310.1371/journal.pone.0053850https://doaj.org/article/2285fe0cfbbf425995582c081c3315302013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23342018/?tool=EBIhttps://doaj.org/toc/1932-6203Breast cancer recurrence (BCR) is a common treatment outcome despite curative-intent primary treatment of non-metastatic breast cancer. Currently used prognostic and predictive factors utilize tumor-based markers, and are not optimal determinants of risk of BCR. Germline-based copy number aberrations (CNAs) have not been evaluated as determinants of predisposition to experience BCR. In this study, we accessed germline DNA from 369 female breast cancer subjects who received curative-intent primary treatment following diagnosis. Of these, 155 experienced BCR and 214 did not, after a median duration of follow up after breast cancer diagnosis of 6.35 years (range = 0.60-21.78) and 8.60 years (range = 3.08-13.57), respectively. Whole genome CNA genotyping was performed on the Affymetrix SNP array 6.0 platform. CNAs were identified using the SNP-Fast Adaptive States Segmentation Technique 2 algorithm implemented in Nexus Copy Number 6.0. Six samples were removed due to poor quality scores, leaving 363 samples for further analysis. We identified 18,561 CNAs with ≥1 kb as a predefined cut-off for observed aberrations. Univariate survival analyses (log-rank tests) identified seven CNAs (two copy number gains and five copy neutral-loss of heterozygosities, CN-LOHs) showing significant differences (P<2.01×10(-5)) in recurrence-free survival (RFS) probabilities with and without CNAs.We also observed three additional but distinct CN-LOHs showing significant differences in RFS probabilities (P<2.86×10(-5)) when analyses were restricted to stratified cases (luminal A, n = 208) only. After adjusting for tumor stage and grade in multivariate analyses (Cox proportional hazards models), all the CNAs remained strongly associated with the phenotype of BCR. Of these, we confirmed three CNAs at 17q11.2, 11q13.1 and 6q24.1 in representative samples using independent genotyping platforms. Our results suggest further investigations on the potential use of germline DNA variations as prognostic markers in cancer-associated phenotypes.Yadav SapkotaSunita GhoshRaymond LaiBradley P CoeCarol E CassYutaka YasuiJohn R MackeySambasivarao DamarajuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e53850 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yadav Sapkota
Sunita Ghosh
Raymond Lai
Bradley P Coe
Carol E Cass
Yutaka Yasui
John R Mackey
Sambasivarao Damaraju
Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
description Breast cancer recurrence (BCR) is a common treatment outcome despite curative-intent primary treatment of non-metastatic breast cancer. Currently used prognostic and predictive factors utilize tumor-based markers, and are not optimal determinants of risk of BCR. Germline-based copy number aberrations (CNAs) have not been evaluated as determinants of predisposition to experience BCR. In this study, we accessed germline DNA from 369 female breast cancer subjects who received curative-intent primary treatment following diagnosis. Of these, 155 experienced BCR and 214 did not, after a median duration of follow up after breast cancer diagnosis of 6.35 years (range = 0.60-21.78) and 8.60 years (range = 3.08-13.57), respectively. Whole genome CNA genotyping was performed on the Affymetrix SNP array 6.0 platform. CNAs were identified using the SNP-Fast Adaptive States Segmentation Technique 2 algorithm implemented in Nexus Copy Number 6.0. Six samples were removed due to poor quality scores, leaving 363 samples for further analysis. We identified 18,561 CNAs with ≥1 kb as a predefined cut-off for observed aberrations. Univariate survival analyses (log-rank tests) identified seven CNAs (two copy number gains and five copy neutral-loss of heterozygosities, CN-LOHs) showing significant differences (P<2.01×10(-5)) in recurrence-free survival (RFS) probabilities with and without CNAs.We also observed three additional but distinct CN-LOHs showing significant differences in RFS probabilities (P<2.86×10(-5)) when analyses were restricted to stratified cases (luminal A, n = 208) only. After adjusting for tumor stage and grade in multivariate analyses (Cox proportional hazards models), all the CNAs remained strongly associated with the phenotype of BCR. Of these, we confirmed three CNAs at 17q11.2, 11q13.1 and 6q24.1 in representative samples using independent genotyping platforms. Our results suggest further investigations on the potential use of germline DNA variations as prognostic markers in cancer-associated phenotypes.
format article
author Yadav Sapkota
Sunita Ghosh
Raymond Lai
Bradley P Coe
Carol E Cass
Yutaka Yasui
John R Mackey
Sambasivarao Damaraju
author_facet Yadav Sapkota
Sunita Ghosh
Raymond Lai
Bradley P Coe
Carol E Cass
Yutaka Yasui
John R Mackey
Sambasivarao Damaraju
author_sort Yadav Sapkota
title Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
title_short Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
title_full Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
title_fullStr Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
title_full_unstemmed Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
title_sort germline dna copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/2285fe0cfbbf425995582c081c331530
work_keys_str_mv AT yadavsapkota germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT sunitaghosh germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT raymondlai germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT bradleypcoe germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT carolecass germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT yutakayasui germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT johnrmackey germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
AT sambasivaraodamaraju germlinednacopynumberaberrationsidentifiedaspotentialprognosticfactorsforbreastcancerrecurrence
_version_ 1718422592665157632